Surrozen Q3 net loss $10.4M; cash $43.4M; Phase 1a data expected Q1 2024

Surrozen, Inc./DE

2023-Q3 EPS reported $1.13

Net loss $10.4M vs $13.4M prior year; R&D expenses down to $6.1M from $8.6M.
Cash and securities $43.4M (Sept 30, 2023), down from $53.4M (June 30, 2023); runway into 2025.
Phase 1a data for SZN-043 and SZN-1326 expected Q1 2024; Phase 1b studies to initiate in 2024.
Two new USPTO patents granted (Nos. 11/746,150 and 11/773,171) for SZN-1326 and SWAP technology.
Boehringer Ingelheim partnership: potential $10M milestone in 2024 upon candidate nomination.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Surrozen, Inc./DE reported the third quarter ended September 30, 2023 results: net income $10.4 million.

Period: the third quarter ended September 30, 2023
Net income: $10.4 million
Result: reported results

Exact text from the filing

Net loss for the third quarter ended September 30, 2023 was $10.4 million, as compared to $13.4 million for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Surrozen, Inc./DE filing history →

Source: SEC EDGAR

accession 0000950170-23-061101

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.